Guide

9 CFR 113 & USDA-CVB: A Practical Readiness Guide for Veterinary Biologics Manufacturers

9 CFR Parts 101–124 govern veterinary biologics in the United States — vaccines, bacterins, antitoxins, diagnostic kits and related products — under USDA-APHIS Center for Veterinary Biologics (CVB). 9 CFR Part 113 sets the standard requirements for licensed biological products; Part 102 covers licensure; Part 103 covers experimental products; Part 113.113 covers autogenous biologics; Part 116/117 cover records and inspection. The CVB regime runs in parallel with FDA-CVM but on a completely different submission, inspection and release model — CVB serial release of every production batch before distribution. This guide walks the integrated 9 CFR framework, the recurring CVB deficiency findings, and a practical path to a defensible veterinary biologics programme.

Start free trial Free trial, no credit card, onboard in days, not months.

Licensed vs autogenous — and what each requires

Licensed biologics under 9 CFR 102/113 require a US Veterinary Biological Product License with a filed Outline of Production (the binding manufacturing recipe), CVB inspection of the establishment, and CVB serial release of every production batch via the Animal and Plant Health Inspection Service. Autogenous biologics under 9 CFR 113.113 are produced from organisms isolated from a specific herd or flock under a veterinarian's prescription — no licensed product but a CVB-inspected facility, a defined facility category, and reduced submission burden in exchange for restricted distribution. A manufacturer doing both runs the licensed-product floor on shared facilities.

The Outline of Production as the binding manufacturing document

9 CFR 114 requires every licensed biologic to operate per an approved Outline of Production. The Outline is not a quality manual — it is the binding recipe that the licence-holder must follow exactly. Any deviation requires either an amended Outline (CVB approval before implementation) or a documented deviation under 9 CFR 116. Recurring deficiency: production records that drift from the Outline over time without an amendment trail, discovered at inspection or at a serial-release failure investigation.

Serial release and the CVB Form 2008 workflow

9 CFR 113 requires every production serial to pass the standard requirements (identity, purity, safety, potency) before release. The manufacturer files release request and supporting test data via CVB; CVB issues the release authorisation. Recurring deficiency: serial release tests filed with thin link back to the validated method or to the master seed/master cell stock; serials released by the manufacturer before CVB authorisation arrives (a regulatory violation regardless of the test outcome).

Master seed/master cell, pre-master and the recurring purity findings

9 CFR 113 sets the master seed and master cell stock requirements — purity, identity, freedom from extraneous agents per the species-and-product-specific test panel. The pre-master to master stock derivation must be documented. Recurring deficiency: extraneous agent testing performed on the working seed but the trace back to the master seed purity is incomplete; or the test panel is current but the validation of the test methods themselves predates the current CVB guidance.

A 90-day readiness path for CVB inspection

Days 1–10: licensed/autogenous scope check and Outline of Production currency audit. Days 11–30: production records vs Outline reconciliation across all active products. Days 31–55: master seed/master cell traceability and extraneous agent testing currency. Days 56–75: serial release authorisation discipline — audit of last 12 months for any pre-authorisation distribution. Days 76–85: facility/equipment vs 9 CFR 108 inspection model. Days 86–90: management review and CVB inspection readiness rehearsal.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

CVB biologics QMS

Outline of Production at the centre.

Master seed traceability

Pre-master to working stock linked end-to-end.

Serial release gating

CVB authorisation required before distribution.

Industries this hits hardest

Veterinary pharma

Frequently asked

Is CVB cGMP the same as FDA cGMP?

No — CVB operates under 9 CFR 113 standard requirements, not 21 CFR 211 cGMP. The two are structurally similar but not identical; the Outline of Production discipline is unique to CVB. A combination programme (CVM drug + CVB biologic) must satisfy both regimes.

How long does serial release take?

CVB targets are published per product category. Routine serials typically clear in days to a few weeks once the release request is filed. Distribution before CVB authorisation is a violation regardless of routine timing — many manufacturers carry inventory pressure that creates the temptation, and that pressure is the audit-trail signal CVB looks for.

Can an autogenous facility be inspected to a lower standard?

9 CFR 113.113 defines autogenous facility categories with specific requirements. The category is lower than a licensed biologic facility but the facility must be inspected and approved by CVB; it is not unregulated. Shared facilities default to the higher floor.

Where does the OIE/WOAH Terrestrial Manual fit?

WOAH Terrestrial Manual chapters set internationally accepted standards for veterinary vaccine test methods and are referenced by CVB guidance for many species. Multi-region manufacturers reference WOAH alongside CVB to keep international submissions aligned.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →